Evidence map›Paper›PMID 29753994›Full record

Trial reportMultiple sclerosis and related disorders2018

Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis.

Kathryn C Fitzgerald, Diane Vizthum, Bobbie Henry-Barron, Amy Schweitzer, Sandra D Cassard, Eric Kossoff, Adam L Hartman, Dimitrios Kapogiannis, Patrick Sullivan, David J Baer and 3 more

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 5 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 5 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Association of serum homocysteine, folate, and vitamin BMultiple sclerosis and related disorders · 2023
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kathryn C FitzgeraldDivision of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States. Electronic address: fitzgerald@jhmi.edu.
Diane VizthumResearch Nutrition, Institute for Clinical and Translational Research, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Bobbie Henry-BarronResearch Nutrition, Institute for Clinical and Translational Research, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Amy SchweitzerResearch Nutrition, Institute for Clinical and Translational Research, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Sandra D CassardDivision of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Eric KossoffDepartments of Neurology and Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Adam L HartmanDepartments of Neurology and Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Dimitrios KapogiannisDepartment of Cellular and Molecular Neuroscience, National Institute on Aging, Baltimore, MD, United States.
Patrick SullivanBeltsville Human Nutrition Research Center, United States Department of Agriculture, Beltsville, MD, United States.
David J BaerBeltsville Human Nutrition Research Center, United States Department of Agriculture, Beltsville, MD, United States.
Mark P MattsonDepartment of Cellular and Molecular Neuroscience, National Institute on Aging, Baltimore, MD, United States.
Lawrence J AppelWelch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Ellen M MowryDivision of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Johns Hopkins University · USNational Institute on Aging · USUnited States Department of Agriculture · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Studies in Dementia and Neurodegenerative DiseasesZIAAG000975 · NIA · NATIONAL INSTITUTE ON AGING · PI KAPOGIANNIS, DIMITRIOS · 2009 to 2025
$31.5M
Intramural NIH HHS Z99 AG999999Intramural NIH HHS ZIA AG000975NCATS NIH HHS UL1 TR001079
6 · The paper itself

Abstract

An intermittent fasting or calorie restriction diet has favorable effects in the mouse forms of multiple sclerosis (MS) and may provide additional anti-inflammatory and neuroprotective advantages beyond benefits obtained from weight loss alone. We conducted a pilot randomized controlled feeding study in 36 people with MS to assess safety and feasibility of different types of calorie restriction (CR) diets and assess their effects on weight and patient reported outcomes in people with MS. Patients were randomized to receive 1 of 3 diets for 8 weeks: daily CR diet (22% daily reduction in energy needs), intermittent CR diet (75% reduction in energy needs, 2 days/week; 0% reduction, 5 days/week), or a weight-stable diet (0% reduction in energy needs, 7 days/week). Of the 36 patients enrolled, 31 (86%) completed the trial; no significant adverse events occurred. Participants randomized to CR diets lost a median 3.4 kg (interquartile range [IQR]: -2.4, -4.0). Changes in weight did not differ significantly by type of CR diet, although participants randomized to daily CR tended to have greater weight loss (daily CR: -3.6 kg [IQR: -3.0, -4.1] vs. intermittent CR: -3.0 kg [IQR: -1.95, -4.1]; P = 0.15). Adherence to study diets differed significantly between intermittent CR vs. daily CR, with lesser adherence observed for intermittent CR (P = 0.002). Randomization to either CR diet was associated with significant improvements in emotional well-being/depression scores relative to control, with an average 8-week increase of 1.69 points (95% CI: 0.72, 2.66). CR diets are a safe/feasible way to achieve weight loss in people with MS and may be associated with improved emotional health.

Indexed as

Weight LossAdultAnthropometryBiomarkersCaloric RestrictionFemaleHumansMaleMultiple Sclerosis, Relapsing-RemittingPatient CompliancePatient Reported Outcome MeasuresPilot ProjectsTreatment OutcomeBiomarkersDietary interventionMultiple sclerosisWeight loss intervention

Identifiers

PMID29753994
PMCPMC6107078
OpenAlexW2799630203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.